The role of c-FLIPL in ovarian cancer: Chaperoning tumor cells from immunosurveillance and increasing their invasive potential

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 451-459

  El Gazzar, Ahmed ^a   Wittinger, Michael ^a   Perco, Paul ^b   Anees, Mariam ^a   Horvat, Reinhard ^a   Mikulits, Wolfgang ^c   Grunt, Thomas W ^a   Mayer, Bernd ^b   Krainer, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; c FLIPL; Immunosurveillance; Ovarian cancer

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS;

EID: 77951937736     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.024     Document Type: Article

References (56)

1. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 (2002) 19-30
2. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
3. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
4. Vaux D.L., and Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 93 (1996) 2239-2244
5. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., et al. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
6. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sci 20 (1995) 198-202
7. Chinnaiyan A.M., O'Rourke K., Tewari M., and Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81 (1995) 505-512
8. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
9. Inohara N., Koseki T., Hu Y., Chen S., and Nunez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci USA 94 (1997) 10717-10722
10. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
11. Djerbi M., Darreh-Shori T., Zhivotovsky B., and Grandien A. Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. Scand J Immunol 54 (2001) 180-189
12. Scaffidi C., Schmitz I., Krammer P.H., and Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274 (1999) 1541-1548
13. Shu H.B., Halpin D.R., and Goeddel D.V. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6 (1997) 751-763
14. Krueger A., Schmitz I., Baumann S., Krammer P.H., and Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276 (2001) 20633-20640
15. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11 (2004) 915-923
16. Song J.H., Song D.K., Herlyn M., Petruk K.C., and Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 9 (2003) 4255-4266
17. L and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 11 (2005) 8585-8591
18. Kataoka T., Schroter M., Hahne M., Schneider P., Irmler M., Thome M., et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 161 (1998) 3936-3942
19. Medema J.P., de Jong J., van Hall T., Melief C.J., and Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190 (1999) 1033-1038
20. Screpanti V., Wallin R.P., Ljunggren H.G., and Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167 (2001) 2068-2073
21. El-Gazzar A., Perco P., Eckelhart E., Anees M., Sexl V., Mayer B., et al. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther 9 (2010) 1007-1018
22. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21 (2001) 5299-5305
23. Panka D.J., Mano T., Suhara T., Walsh K., and Mier J.W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 (2001) 6893-6896
24. Wang W., Prince C.Z., Mou Y., and Pollman M.J. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 277 (2002) 21723-21729
25. Abedini M.R., Muller E.J., Brun J., Bergeron R., Gray D.A., and Tsang B.K. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 68 (2008) 4511-4517
26. Fukazawa T., Fujiwara T., Uno F., Teraishi F., Kadowaki Y., Itoshima T., et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20 (2001) 5225-5231
27. Freedman R.S., Pihl E., Kusyk C., Gallager H.S., and Rutledge F. Characterization of an ovarian carcinoma cell line. Cancer 42 (1978) 2352-2359
28. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47 (1987) 414-418
29. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25 (2006) 838-848
30. Banno T., Gazel A., and Blumenberg M. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 280 (2005) 18973-18980
31. Esumi H., Lu J., Kurashima Y., and Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95 (2004) 685-690
32. Santoso J.T., Tang D.C., Lane S.B., Hung J., Reed D.J., Muller C.Y., et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 59 (1995) 171-178
33. Horak P., Pils D., Haller G., Pribill I., Roessler M., Tomek S., et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3 (2005) 335-343
34. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94 (2004) 107-114
35. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., and Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95 (2004) 777-783
36. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007) 166-180
37. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10 (2004) 3291-3300
38. Hendrix N.D., Wu R., Kuick R., Schwartz D.R., Fearon E.R., and Cho K.R. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66 (2006) 1354-1362
39. Goltsev Y.V., Kovalenko A.V., Arnold E., Varfolomeev E.E., Brodianskii V.M., and Wallach D. CASH, a novel caspase homologue with death effector domains. J Biol Chem 272 (1997) 19641-19644
40. Srinivasula S.M., Ahmad M., Ottilie S., Bullrich F., Banks S., Wang Y., et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 272 (1997) 18542-18545
41. Siegel R.M., Martin D.A., Zheng L., Ng S.Y., Bertin J., Cohen J., et al. Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Cell Biol 141 (1998) 1243-1253
42. Yeh W.C., Itie A., Elia A.J., Ng M., Shu H.B., Wakeham A., et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12 (2000) 633-642
43. Rancourt C., Rogers B.E., Sosnowski B.A., Wang M., Piche A., Pierce G.F., et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 4 (1998) 2455-2461
44. Stackhouse M.A., Buchsbaum D.J., Grizzle W.E., Bright S.J., Olsen C.C., Kancharla S., et al. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Int J Radiat Oncol Biol Phys 42 (1998) 817-822
45. Wang M., Rancourt C., Navarro J.G., Krisky D., Marconi P., Oligino T., et al. High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol 71 (1998) 278-287
46. Budzynski W., and Radzikowski C. Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol 16 (1994) 319-346
47. Radzikowski C., Rygaard J., Budzynski W., Stenvang J.P., Schou M., Vangsted A., et al. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice. APMIS 102 (1994) 481-488
48. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
49. Dohrman A., Kataoka T., Cuenin S., Russell J.Q., Tschopp J., and Budd R.C. Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-kappa B activation. J Immunol 174 (2005) 5270-5278
50. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 10 (2000) 640-648
51. Kataoka T., and Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol 24 (2004) 2627-2636
52. Chau H., Wong V., Chen N.J., Huang H.L., Lin W.J., Mirtsos C., et al. Cellular FLICE-inhibitory protein is required for T cell survival and cycling. J Exp Med 202 (2005) 405-413
53. Zhang N., Hopkins K., and He Y.W. The long isoform of cellular FLIP is essential for T lymphocyte proliferation through an NF-kappaB-independent pathway. J Immunol 180 (2008) 5506-5511
54. Reed J.C., and Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 106 (2005) 408-418
55. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 25 (2005) 31-58
56. Li F.Y., Jeffrey P.D., Yu J.W., and Shi Y. Crystal structure of a viral FLIP: insights into FLIP-mediated inhibition of death receptor signaling. J Biol Chem 281 (2006) 2960-2968